The anti-inflammatory and anti-viral effects of an ethnic medicine: Glycyrrhizin

Journal of Medicinal Plants

Volumn 9, Issue SUPPL 6., 2010, Pages 1-28

  Shamsa, F ^a   Ohtsuki, K ^b   Hasanzadeh, E ^c   Rezazadeh, Sh ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Anti inflammatory; Anti viral; Glycyrrhizin; Review

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; 3 MONOGLUCURONYLGLYCYRRHETINIC ACID; ANGIOGENIN; ARACHIDONIC ACID; CASEIN KINASE I; CASEIN KINASE II; CELL NUCLEUS RECEPTOR; CELL PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOSPORIN A; GLUCOCORTICOID RECEPTOR; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE H2A; HISTONE H2B; HYALURONIDASE; INTERFERON; LACTOFERRIN; LIPOXYGENASE; NEOMINOPHAGEN C; PHOSPHOLIPASE A2; PREDNISOLONE; PROSTAGLANDIN E2; RNA DIRECTED DNA POLYMERASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AIDS RELATED COMPLEX; ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; DISORDERS OF STEROID METABOLISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEPATITIS B; HEPATITIS C; HEPATITIS E; HERPES VIRUS INFECTION; HUMAN; HYPOKALEMIA; INFLAMMATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PROTEIN INDUCTION; PSEUDOALDOSTERONISM; REVIEW; VIRUS HEPATITIS; VIRUS REPLICATION;

DNA VIRUSES; GLYCYRRHIZA; GLYCYRRHIZA GLABRA;

EID: 77958526426     PISSN: 2717204X     EISSN: 27172058     Source Type: Journal    
DOI: None     Document Type: Review

References (171)

1. Akao T, Hattori M, Kanaoka M, Yamamoto K, Namba T, Kobashi K. Hydrolysis of glycyrrhizin to 18-β-glycyrrhetyl monoglucuronide by lysosomalβ-D-glucuronidase of animal livers. Biochem. Pharmacol. 1991; 41: 1025-9.
2. Akao T, Hayashi T, Kobashi K, Kanaoka M, Kato H, Kobayashi M, Takeda S, Oyama T. Intestinal bacterial hydrolysis is indispensable to absorption of 18β-glycyrrhetic acid after oral administration of glycyrrhizin in rats. J. Pharm. Pharmacol. 1994; 46: 135-7. (Pubitemid 24070843)
3. Akao T. Localization of enzymes involved in metabolism of glycyrrhizin in contents of rat gastrointestinal tract. Biol. Pharm. Bull. 1997; 20: 122-6.
4. Hattori M, Sakamoto T, Yamagishi T, Sakamoto K, Konoshiki K, Kobashi K, Namba T. Metabolism of glycyrrhizin by human intestinal flora. II. Isolation and charaterization of human intestinal bacteria capable of metabolizing glycyrrhizin and related compounds. Chem. Pharm. Bull. 1985; 33: 210-7. (Pubitemid 15130851)
5. Tanaka N. Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitis. Biopharm. Drug Dispos 1993; 14: 609-14.
6. Ishida S, Yamamura Y, Santa T. Disposition of glycyrrhizin in the perfused liver of rats. Biol. Pharm. Bull. 1994; 17: 960-9.
7. Cantelli-Forti G, Maffei F, Hrelia P, Bugamelli F, Bernardi M, D'Intino P, et al. Interaction of licorice on glycyrrhizin pharmacokinetics. Environ Health Perspect. 1994; 102 Suppl. 9: 65-68.
8. Raggi MA, Maffei F, Bugamelli F, Cantelli Forti G. Bioavailability of glycyrrhizin and licorice extract in rat and human. Plasma as detected by HPLC method. Pharmazie 1994; 49: 269-72. (Pubitemid 24119930)
9. Wang Z, Nishioka M, Kurosaki Y, Nakayama T, Kimura T. Gastrointestinal absorption characteristics of glycyrrhizin from glycyrrhiza extract. Biol. Pharm. Bull. 1995; 18: 1238-41.
10. Wang Z, Okamoto M, Kurosaki Y, Nakayama T, Kimura T. Pharmacokinetics of glycyrrhizin in rats with D-galactosamine-induced hepatic disease. Biol. Pharm. Bull., 1996; 19: 901-4.
11. Takeda S, Ishihara K, Wakui Y., Amagaya S, Maruno M, Akao T, Kobashi K. Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. J. Pharm. Pharmacol. 1996; 48: 902-5.
12. Yamamura Y, Kotaki H, Tanaka N, Aikawa T, Sawada Y, Iga T. The pharmacokinetics of glycyrrhizin and its restorative effect on hepatic function in patients with chronic hepatitis and in chronically carbon-tetrachloride- intoxicated rats. Biopharm. Drug Dispos. 1997; 18: 717-25.
13. Shamsa F, Nagata N, Oh-Ishi M, Ohtsuki K. The in vitro effects of glycyrrhizin and the derivatives of glycyrrhetinic acid on the activity of cAMP-dependent protein kinase and phosphorylation of cellular polypeptide by the kinase from Ehrlich ascites tumor cells. Tohoku J. Exp. Med. 1991; 165: 305-18.
14. Shamsa F, Iwasa T, Saito H, Nagata N, Ohtsuki K. The biological significance of glycyrrhizin and glycyrrhetinic acid derivative induced selective phosphorylation of histones H2A and H2B by A-kinase in vitro. Tohoku J. Exp. Med. 1994; 172: 123-32. (Pubitemid 24180201)
15. Abe Y, Shimoyama Y, Munakata H, Ito J, Nagata N, Ohtsuki K. Characterization of an apoptosis-inducing factor in Habu snake venom as a glycyrrhizin (GL)-binding protein potently inhibited by GL in vitro. Biol. Pharm. Bull. 1998; 21: 924-7.
16. Furuya T, Yamagata S, Shimoyama Y, Fujihara M, Morishima N, Ohtsuki K. Biochemical characterization of glycyrrhizin as an effective inhibitor for hyaluronidases from bovine testis. Biol. Pharm. Bull. 1997; 20: 973-7.
17. Shimoyama Y, Ohtaka H, Nagata N, Ohtsuki K. physiological correlation between glycyrrhizin, glycyrrhizin-binding lipoxygenase and casein kinase II. FEBS Lett. 1996; 12: 238-42.
18. Haneda E, Furuya T, Asai S, Morikawa Y, Ohtsuki K. Biochemical characterization of casein kinase II as a protein kinase responsible for stimulation of HIV-1 protease in vitro. Biolchem. Biophys. Res. Commun. 2000; 275: 434-9.
19. Harada S, Maekawa T, Haneda E, Morikawa Y, Nagata N, Ohtsuki K. Biochemical characterization of recombinant HIV-1 reverse transcriptase (rRT) as a glycyrrhizin-binding protein and the CKII-mediated stimulation of rRT activity potently inhibited by glycyrrhetinic acid derivative. Biol. Pharm. Bull. 1998; 21: 1282-5. (Pubitemid 29021786)
20. Ohtsuki K, Abe Y, Shimoyama Y, Furuya T, Munakata H, Takasaki C. Separation of phospholipase A2 in Habu snake venom by glycyrrhizin-affinity column chromatography and identification of a GL-sensitive enzyme. Biol. Pharm. Bull. 1998; 21: 574-8.
21. Hattori T, Ikematsu S, Koito A, Matsushita S, Maeda Y. Preliminary evidence for inhibitory effect of glycyrrhizin on HIV replication patients with AIDS. Antiviral Res. 1989; 11: 255-62.
22. Crance JM, Biziagos E, Passagot J, Van Cuyck-Gandre, Deloince R. Inhibition of hepatitis A virus replication in vitro by antiviral compounds. J. Med. Virol., 1990; 31: 155-60.
23. Crance JM, Leveque F, Biziagos E. Studies on mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro. Antiviral Res. 1994; 23: 63-76. (Pubitemid 24021216)
24. Takahara T. Effects of glycyrrhizin on hepatitis B surface antigen: a biochemical and morphological study. J. Hepatol., 1994; 21: 601-9.
25. Da Nagao Y. Effectiveness of glycyrrhizin for oral lichen planus in patients with chronic HCV infection. J. Gastroenterol., 1996; 31: 691-5.
26. Arase Y. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 15: 1494-500.
27. Numazaki K. Effect of glycyrrhizin in children with liver dysfunction associated with cytomegalovirus infection. Tohoku J. Exp. Med. 1994; 172: 147-53.
28. Agarwal R. Inhibition of mouse skin tumor-initiating activity of DMBA by chronic oral feeding of glycyrrhizin in drinking water. Nutr. Cancer 1991; 15: 187-93.
29. Suzuki F. Stimulation of host resistance against tumors by glycyrrhizin, an active component of licorice roots. In Vivo 1992; 6: 589-96. (Pubitemid 23057261)
30. Shiota G, Harada K, Ishida M, Tomie Y, Okubo M, Katayama S. Inhibition of hepatocellular carcinoma by glycyrrhizin in diethyl nitrosamine treated mice. Carcinogenesis 1999; 20: 59-63.
31. Patrick L. Hepatitis C: Epidemiology and review of complementary/ alternative medicine treatments. Altern. Med. Rev., 1999; 4: 220-38.
32. Kumagai A, Yano S, Otomo M, et al. Study on the corticord-like action of glycyrrhizin and mechanism of its action. Endocrinol. Jpn. 1957; 4: 17-27.
33. Stwart PW, Wallace AM, Valentino R. et al. Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase defficiency comes of age. Lancent 1987; 2: 281-4.
34. Kageyama Y. Renin-dependency of glycyrrhizin-induced pseudoaldosteronism. Endocrinol Jpn. 1991; 38: 103-8.
35. Kageyama Y, Suzuki H. Saruta T. Glycyrrhizin induces mineralocorticoid activity through alterations in cortisol metabolism in the human kidney. J. Endocrinol. 1992; 135: 147-52.
36. Finney RSH, Somers GD. The anti-inflammatory activity of glycyrrhetinic acid and derivatives. J. Pharmacol. (London), 1959; 10: 613-20.
37. Nasyrov KM, Lazareva DN. Anti-inflammatory activity of glycyrrhizic acid derivatives. Farmakol. Toksikol. 1980; 43: 399-404.
38. Ohuchi K, Kamada Y, Levine L, Tsurufuji S. Glycyrrhizin inhibits prostaglandin E2 production by activated peritoneal macrophages from rats. Prostaglandins Med. 1981; 7: 457-63. (Pubitemid 12249608)
39. Zhang HQ, Liu F, Sun B, Li GH. Anti-allergic action of glycyrrhizin. Chung Kuo Yao Li Hsueh Pao. 1986; 7: 175-177 (in Chinese).
40. Pompei R, Flore O, Marccialis MA, Pani A, Loddo B. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature, 1979; 281: 689-90.
41. Abe N, Ebina T, Ishida N. Interferon induction by glycyrrhizin and glycyrrhitinic acid in mice. Microbiol. Immunnol. 1982; 26: 535-9.
42. Ito K, Kumagai K. Augmentation of NK cell activity by several anti-inflmmatory agents. Excerpta Med. 1983; 641: 460-64.
43. Kimura M, Watanabe H, Abo T. Selective activation of extrathymic T cells in the liver by glycyrrhizin. Biotheraphy 1992; 5: 167-76.
44. Nakajima N, Utsunomiya T, Kobayashi M, Herndon DN, Pollard RB, Suzuki F. In vitro induction of anti-type 2 T cells by glycyrrhizin. Burns 1996; 22: 612-7. (Pubitemid 27011689)
45. Dai JH, Iwatani Y, Ishida T, Terunuma H, Kasai H, Iwakula Y, Fujiwara H, Ito M. Glycyrrhizin enhances interleukin-12 production in peritoneal macrophages. Immunol. 2001; 103: 235-43.
46. Utsunomiya T, Kobayashi M, Ito M, Herndon DN, Pollard RB, Suzuki F. Glycyrrhizin restores the impaired IL-12 production in thermally injured mice. Cytokine 2001; 14: 49-55.
47. Suzuki F, Kobayashi M, Utsunomiya T, Sasaki H, Pollard RB. The induction of β -chemokines by glycyrrhizin, an active component of licorice roots, in cultures of peripheral blood mononuclear cells. J. Allergy Clin. Immunol. 2000; 105: S113.
48. Ulmann A, Menard J, Corvol P. Binding of glycyrrhetinic acid to kidney mineralcorticoid and glucocorticoid receptor. Endocrinol. 1975; 97: 46-51.
49. Shiki Y, Ishikawa Y, Shirai K, Saito Y, Yoshida S. Effect of glycyrrhizin on lysosomes labilization by Phosphorylase A2. Amer. J. Chi. Med. 1986; 14: 131-7.
50. Su XS, Chen HM, Wang LH, Jiang CF, Liu JH. Clinical and laboratory observation on the effect of glycyrrhizin in acute and chronic viral hepatitis. J. Tradit. Chin. Med. 1984; 4: 127-32.
51. Baba M, Shigita S. Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro. Antimicrob. Agents Chemother. 1987; 25: 515-7.
52. Ito M, Nakanishi H, Baba M, Pauwels R, Clercq E, Shigeta S, Yamamoto N. Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopatheic activity of human immunodeficiency virus [HIV (HTLV-III/LAV)]. Antiviral Res. 1987; 7: 127-37.
53. Hirabayashi K, Iwata S, Matsumoto H, Mori T, Shibata S, Baba M, Ito M, et al. Antiviral activities of glycyrrhizin and its modified compounds against human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 1 (HSV-1) in vitro. Chem. Pharm. Bull. 1991; 39: 112-5.
54. Mori K, Sakai H, Suzuki S, Akutsu Y, Ishikawa M, Imaizumi M, et al. Effects of glycyrrhizin (SNMC: Stronger Neo-Minophagen C) in hemophilia patients with HIV-1 infection. Tohoku J. Exp. Med. 1990; 162: 183-93.
55. Van Rossum TGJ, Voulto AG, De Man RA, Brouwer JT, Schalm SW. Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment. Pharmacol. Ther. 1998; 12: 199-205 (review).
56. Miyamura M, Ono M, Kyotani S, Nishioka Y. Properties of glycyrrhizin in Kampo extracts including licorice root and changes in the blood concentration of GA after oral administration of Kampo extracts. Yakugaku Zasshi 1996; 116: 209-16. (Pubitemid 26120612)
57. Yamamura Y, Santa T, Kotaki H, Uchino K, Sawada Y, Iga T. Administration-route dependency of absorption of glycyrrhizin in rats: intraperitoneal administration dramatically enhanced bioavailability. Biol. Pharm. Bull. 1995; 18: 337-41.
58. Ploeger B, Mensinga T, Sips A, Seinen W, Meulenbelt J, DeJongh J. The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetics modeling. Drug. Metab. Rev. 2001; 33: 125-47.
59. Imai T, Sakai M, Ohtake H, Azuma H, Otagiri M. In vitro and in vivo evaluation of the enhancing activity of glycyrrhizin on the intestinal absorption of drugs. Pharm. Res. 1999; 16: 80-6.
60. Tanaka M, Kuwahara E, Takahashi M, Koyama O, Takahashi N, Yotsunyanagi T. Enhanced rectal absorption of amphotericin B lyophilized with glycyrrhizinate in rabbits. Biol. Pharm. Bull. 1998; 21: 853-7. (Pubitemid 28407234)
61. Chen MF, Shimada F, Kato H, Yano S, Kanaoka M. Effect of oral administration of glycyrrhizin on the pharmacokinetics of prednisolone. Endocrinol. Jpn., 1991; 38: 167-74.
62. Ishiwata S, Nakashita K, Niizeki M, Suzuki N, Kaneko S, Tomioka Y, Hishinuma T, Mizugaki M. Determination of serum concentrations of glycyrrhizin in humans by semi-micro high-performance liquid chromatography after administration of a therapeutic dose. Biol Pharm Bull. 2000; 23: 904-5.
63. Shan S, Tanaka H, Shoyama Y. Enzyme-linked immunosorbent assay for glycyrrhizin using anti-glycyrrhizin monoclonal antibody and an eastern blotting technique for glucuronides of glycyrrhetic acid. Anal. Chem. 2001; 73: 5784-90.
64. Ishida S. Glycyrrhizin binding site on human serum albumin. Chem. Pharm. Bull., 1992; 40: 275-8.
65. Sakamoto R, Okano M, Takena H, Ohtsuki K. Inhibitory effect of glycyrrhizin on phosphorylation and DNA-binding abilities of high mobility group proteins 1 and 2 in vitro. Biol. Pharm. Bull. 2001; 24: 906-11. (Pubitemid 32750316)
66. Ohtsuki K, Oh-Ishi N, Nagata N. The stimulatory and inhibitory effects of glycyrrhizin and a glycyrrhetinic acid derivative on phosphorylation of lipcortin by A-kinase in vitro. Biolchem. Internal. 1992; 28: 1045-53.
67. Ohtsuki K, Ishida N. Inhibitory effect of glycyrrhizin on polypeptide phosphorylation by polypeptide-depedent protein kinase (kinase P) in vitro. Biolchem. Biophys. Res. Commun. 1988; 157: 597-604.
68. Ishikawa A, Kanamaru R, Kakui A, Kanno S, Ohtsuki K. Characterization of glycyrrhizin-binding protein kinase from the crude membrane fraction of rat liver. Biolchem. Biophys. Res. Commun. 1990; 167: 876-82. (Pubitemid 20113263)
69. Ohtsuki K, Oh-Ishi M, Karino A, Kanekatsu M, Shamsa F. Purification and characterization of a 100 kDa glycyrrhizin-binding protein (gb100) as an effective phosphate acceptor for CK-II the effect of GL on the phosphorylation of gb100 by CK-II in vitro. Biolchem. Biophys. Res. Commun. 1994; 198: 1090-8.
70. Harada S, Karino A, Shimoyama Y, Shamsa F, Ohtsuki K. Identification of glycyrrhizin-binding protein kinase as casein kinase II and characterization of its associated phosphate acceptors in mouse liver. Biochem. Biophys. Res. Commun. 1996; 227: 102-9.
71. Hatomi M, Tanigawa K, Fujihara M, Ito J, Yanahira S, Ohtsuki K. Characterization of bovine and human lactoferrins as glycyrrhizin-binding proteins and their phosphorylation in vitro by CK-II. Biol. Pharm. Bull. 2000; 23: 1167-72.
72. Shimoyama Y, Sakamoto R, Akaboshi T, Tanaka M, Ohtsuki K. Characterization of secretory type IIA phospholipase A2 (sPLA2-IIA) as a glycyrrhizin-binding protein and the GL-induced inhibition of the CK-II- mediated stimulation of sPLA2-IIA activity in vitro. Biol. Pharm. Bull. 2001; 24: 1004-8. (Pubitemid 32894118)
73. Tanigawa K, Fujihara M, Furuya T, Shimoyama Y, Morishima N, Ohtsuki K. Biochemical characterization of bovine lactoferrin as glycyrrhizin-binding protein in vitro. Biol. Pharm. Bull. 2000; 23: 438-42.
74. Tanigawa K, Fujihara M, Sakamoto R, Yanahira S, Ohtsuki K. Characterization of bovine angiogenein-1 and lactogenin-like protein as glycyrrhizin-binding proteins and their in vitro phosphorylation by C-kinase. Biol. Phram. Bull. 2001; 24: 443-7.
75. Kawakami F, Shimoyama Y, Ohtsuki K. Characterization of complement C3 as a glycyrrhizin-binding protein and the phosphorylation of C3a by CK-2, which is potently inhibited by GL and GA in vitro. J. Biochem. 2003; 133: 231-7.
76. Lampi G, Deidda D, Pinza M, Pompei R. Enhancement of anti-herpetic activity of glycyrrhizic acid by physiological proteins.Antivir. Chem. Chemother. 2001; 12: 125-31. (Pubitemid 32808173)
77. Maekawa T, Kosuge S, Sakamoto S, Funayama S, Komiyama K, Ohtsuki K. Biochemical characterization of 60S acidic ribosomal P proteins associated with CK-II from bamboo shoots and potent inhibitors of their phosphorylation in vitro. Biol. Pharm. Bull. 1999; 22: 667-73.
78. Francischetti TM, Monteiro RQ, Guimaraes JA. Identification of glycyrrhizin as a thrombin inhibitor. Biochem. Biophys. Res. Commun. 1997; 235: 259-63.
79. Akamatsu H, Komura J, Asada Y, Niwa Y. Mechanism of anti-inflammatory action of glycyrrhizin: effect on neutrophil functions including reactive oxygen species generation. Planta Med. 1991; 57: 119-21.
80. Nose M, Ito M, Kamimura K, Shimizu M, Ogihara Y. A comparison of the antihepatotoxic activity between glycyrrhizin and glycyrrhetinic acid. Planta Med. 1994; 60: 136-9.
81. Nagai T, Egashira T, Yamanaka Y, Kohno M. The protective effect of glycyrrhizin against injury of the liver caused by ischemia-reperfusion. Arch. Environ. Contam. Toxicol. 1991; 20: 432-6.
82. Shiki Y, Shirai K, Saito Y, Yoshida S, Mori Y, Wakashin M. Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrane antibody. J. Gastroenterol. Hepatol. 1992; 7: 12-16.
83. Park EJ. Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction. Biol. Pharm. Bull. 1997; 20: 417-20.
84. Yoshikawa M, Matsui Y, Kawamoto H, Umemoto N, Oku K, Koizumi M. Effects of glycyrrhizin on immune-mediated cytotoxicity. J. Gastroenterol. Hepatol. 1997; 12: 243-8.
85. Tischfield JA. A reassessment of the low molecular weight phospholipase A2 gene family in mammals. J. Biol. Chem. 1997; 272: 17247-17250.
86. Ohtsuki K, Nakamura S, Shimoyama Y, Shibata D, Munakata H, Yoshiki Y, Okubo K. A 96-kDa glycyrrhizin-binding protein (gp96) from soybeans acts as a substrate for casein kinase II, is highly related to lipoxygenase 3. J. Biochem. 1995; 118: 1145-50.
87. Okimasu E, Moromizato Y, Watanabe S, Sasaki J, Shiraishi N, Morimoto YM, Miyahara M, Utsumi K. Inhibition of Phospholipase A2 and platelet aggregation by glycyrrhizin. Acta Med. Okayama 1983; 37: 385-91.
88. Kimura M, Kimura I, Kimura M. Decreasing effects by glycyrrhizin and paeoniflorin on intracellular Ca2+-aequorin luminescence transients with or without caffiene in directly stimulated-diaphragm muscle of mouse. Jpn. J. Pharmacol. 1985; 39: 387-90.
89. Quadroni M, James P, Carafoli E. Isolation of phosphorylated calmodulin from rat liver and identification of the in vivo phosphorylation sites. J. Biol. Chem. 1994; 269: 16116-22.
90. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Sci. 1983; 220: 568-75. (Pubitemid 13130140)
91. Needleman P, Turk J, Jackschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu. Rev. Biochem. 1986; 55: 69-102.
92. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Sarhan CN. Leukotrienes and Lipoxins: structures, biosynthesis, and biological effects. Sci. 1987; 237: 1171-6.
93. Sigal E. The molecular biology of mammalian arachidonic acid metabolism. Am. J. Physio. 1991; 260: L13-L28.
94. Allende JE, Allende CC. Protein kinase 4. protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB. J. 1995; 9: 313-323.
95. Koike T, Ohtsuki K. Purification and characterization of a 400 kDa nonhistone chromatin protein that serves as an effective phosphate acceptor for casein kinase II from Ehrlich ascites tumor cells. J. Biolchem. 1988; 103: 928-37.
96. Ohtsuki K, Matasumoto M, Saito H, Kato T. Characterization of casein kinas II, and of p98 as one of its effective phosphate acceptors in sea urchin eggs. J. Biolchem. 1993; 113: 334-42.
97. Ohtsuki K, Nishikawa Y, Saito H, Munakata H, Kato T. DNA-binding sperm proteins with oligo-arginine clusters functions as potent activators for egg CK-II. FEBS Lett., 1996; 378: 115-20.
98. Gross SD, Anderson RA. Casein kinase I: spatial organization and positioning of a multifunctional protein kinase family. Cell Signal 1998; 10: 699-711.
99. Karino A, Okano M, Hatomi M, Nakamura T, Ohtsuki K. Biochemical characterization of a casein kinase I-like actin kinase responsible for the actin-induced suppression of CK-II activity in vitro. Biochem. Biophys. Acta. 1999; 1472: 603-16.
100. Okano M, Kano S, Munakata H, Ohtsuki K. Biochemical characterization of cholesterol-3-sulfate as the sole effector for the phosphorylation of HMG1 by CK-I in vitro. Biolchem. Biophys. Res. Commun., 2001; 281: 1325-30. (Pubitemid 32924565)
101. Tamura Y, Nishikawa T, Yamada K. Effect of glycyrrhetinic acid and its derivatives on A4-5a- and 5B-reductase in rat liver. Arzneim-Forsh/Drug Res. 1979; 29: 647-9.
102. Tanahashi T, Mune T, Morita H, Tanahashi H, Isomura Y, Suwa T, Daido H, Gomez-Sanchez CE, Yasuda K. Glycyrrhizic acid suppresses type 2 11β-hydroxysteroid dehydrogenase expression in vivo. J. Steroid Biochem. Mol. Biol. 2002; 80: 441-7.
103. Kato H, Kanaoka M, Yano S, Kobayashi M. 3-Monoglucuronyl-glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism. J. Clin. Endocrinol. Metab. 1995; 80: 1929-33.
104. Shimoyama Y, Hirabayashi K, Matsumoto H, Sato T, Shibata S, Inoue H. Effects of glycyrrhetinic acid derivatives on hepatic and renal 11β-hydroxysteroid dehydrogenase activties in rats. J. Phram. Pharm. 2003; 55: 811-7.
105. Zhang YH, Isobe K, Nagase F, Lwin T, Kato M, Hamaguchi M. Glycyrrhizin as a promoter of the late signal transduction for interleukin-2 production by splenic lymphocytes. Immunol. 1993; 79: 528-34.
106. Zhang YH, Kato M, Isobe K, Hamaguchi M, Yokochi T, Nakashima I. Dissociated control by glycyrrhizin of proliferation and IL-2 production of murine thymocytes. Cell Immunol. 1995; 162: 97-104.
107. Retzlaff C, Yamamoto Y, Okubo S, Hoffman PS, Friedman H, Klein TW. Legionella pneumophila heat-shock protein-induced increase of interleukin-1 mRNA involves protein kinase C signalling in macrophages. Immunol. 1996; 89: 281-8.
108. Bost KL, Mason MJ. Thapsigargin and cyclopiazonic acid initiate rapid and dramatic increase of IL-6 mRNA expression and IL-6 secretion in murine peritoneal macrophages. J. Immunol. 1995; 155: 285-96.
109. Ahamed A, Tsunami S, Amakawa T. Triterpenoid saponins stimulate the sugar taste receptor cell through a G protein-mediated mechanism in the blowfly, Phormia regina. J Insect Physiol. 2002; 48: 367-4.
110. Hsiang CY, Lai TL, Chao DC, Ho TY. Differential regulation of activator protein 1 activity by glycyrrhizin. Life Sci. 2002; 70: 1643-56.
111. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Sci. 1999; 285: 248-51.
112. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery, 1999; 126: 389-92.
113. Badam L. In vitro antiviral activity of indigenous glycyrrhizin, licorice and glycyrrhizic acid on Japanese encephalitis virus. J. Commun. Dis. 29: 91-9.
114. Utsunomiya T, Kobayashi M, Pollard RB, Suzuki F. Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. Antimicrob. Agents Chemother. 1997; 41: 551-6.
115. Tandon A, Tandon BN, Bhujiwala RA. Clinical spectrum of acute sporadical hepatitis E and possible benefit of glycyrrhizin therapy. Hepatol. Res. 2002; 23: 55-61.
116. Watanbe H, Miyaji C, Makino M, Abo T. Therapeutic effects of glycyrrhizin in mice infected with LP-BM5 murine retrovirus and mechanisms involved in the prevention of disease progression. Biotherapy 1996; 9: 209-20.
117. Sasaki H, Takei M, Kobayashi M, Suzuki F. Effect of glycyrrhizin, an active component of licorice roots, on HIV replication in cultures of peripheral blood mononuclear cells from HIV-seropotive patients. Phathobilog 2002; 70: 229-36.
118. Crance JM, Scaramozzino N, Jouan A, Garin D. Interferon, riavirin, 6-azauridine and glycyrrhizin: anti-viral components active against pathogenic flaviviruses. Antiviral Res. 2003; 58: 73-9.
119. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active compound of liquorice roots, and replication of SARS-associated Coronavirus. Lancent 2003; 361: 2045-6.
120. Sato H, Goto W, Yamamura J, Kurokawa M, Kageyama S, Takahara T. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res. 1996; 30: 171-7.
121. Numazaki K, Nagata N, Sato T, Chiba S. Effect of glycyrrhizin, cyclosporin A, and tumor necrosis factor-α on infection of U-937 and MRC-5 cells by human cytomegalovirus. J. Leukoc. Biol. 1994; 55: 24-8.
122. Utsunomiya T, Kobayashi M, Herndon DN, Pollard RB, Suzuki F. Glycyrrhizin improves the resistance of thermally injured mice to opportunistic infection of herpes simplex virus type 1. Immunol. Lett. 1995; 44: 59-66.
123. Teodoro JG, Halliday T, Whalen SG, Takayesu D, Graham FL, Branton PE. Phosphorylation at the carboxy terminus of the 55 kDa adenovirus type 5 E1B protein regulates transforming activity. J. Virol. 1994; 68: 776-86. (Pubitemid 24022180)
124. Massimi P, Pim D, Banks L. HPV-16 and adenovirus E1a complex formation with TATA box binding protein is enhanced by CK-II phosphorylation. Onocogene 1996; 12: 2325-30.
125. Schwemmle M, De B, Shi L, Banerjee A, Lipkin WI. Borna disease virus P-protein is phosphorylated by protein kinase C epsilon and casein kinase II. J. Biol. Chem. 1997; 272: 21818-23.
126. McShan GD, Wilson VG. Casein kinase II phosphorylates bovine papillomavirus type 1 E1 in vitro at a conserved motif. J. Gen. Virol. 1977; 78: 171-7.
127. Liu Z, Huntley CC, De BP, Das T, Banerjii AK, Oglesbee ML. Phosphorylation of canine distemper virus P protein by protein kinase C-zeta and casein kinase II. Virology 1997; 232: 198-206.
128. Grasser FA, Gottel S, Haiss P, Boldyreff B, Issinger OG, Mueller-Lantzsch N. Phosphorylation of the Epstein-Barr virus nuclear antigen 2. Biochem. Biophys. Res. Commun. 1992; 14: 1694-701.
129. Kolmann JL, Taylor N, Marshak DR, Miller G. Serine-173 of the Epstein-Barr virus ZEBRA protein is required for DNA-binding and is a target for CK-II phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 1993; 90: 10115-9.
130. Cook ID, Shanahan F and Farrell PJ. Epstein-Barr virus SM protein. Virology 1994; 15: 217-27.
131. Bogner E, Anheier B, Offner F, Smuda C, Reschke M, Eickmann M, Radsak K. Nuclear translocation of mutagenized forms of human cytomegalovirus glycoprotein B (gpUL55). J. Gen.Virol 1997; 78: 11647-51.
132. Fish KN, Soderberg-Naucler C, Nelson JA. Steady-state plasma membrane expression of human cytomegalovirus gB is determined by the phosphorylation state of Ser 900. J. Virol. 1998; 72: 6657-64.
133. Coates K, Cooke SJ, Mann DA, Harris MPG. Protein kinase C-mediated phosphorylation of HIV-1 Nef in human cell lines. J. Biol. Chem. 1997; 272: 12289-94.
134. Coates K, Harris M. The human immunodeficiency virus type 1 Nef protein functions as a protein kinase C substrate in vitro. J. Gen. Virol. 1995; 76: 837-44.
135. Vincent MJ, Abdul Jabbar M. The human immunodeficiency virus type 1 Vpu protein: a potential regulator of proteolysis and protein transport in the mammalian secretory pathway. Virology 1995; 213: 639-49.
136. Friborg J, Ladha A, Gottlinger H, Haseltine WA, Cohen EA. Functional analysis of the phosphorylation sites on the human immunodeficiency virus type 1 Vpu protein. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995; 8: 10-22.
137. Mazumder B, Barik S. Requirement of casein kinase II-mediated phosphorylation for the transcriptional activity of human respiratory syncytial viral phosphoprotein P: transdominant negative phenotype of phosphorylation- defective P mutants. Virology 1994; 205: 104-11.
138. Villanueva N, Navarro J, Mendez E, Garcia-Albert I. Identification of a protein kinase involved in the phosphorylation of the C-terminal region of human respiratory syncytial virus P protein. J. Gen. Virol. 1994; 75: 555-65.
139. Wadd S, Bryant H, Filhol O, Scott JE, Hsieh TY, Everett RD, Clements JB. The multifunctional herpes simplex virus IE63 protein interacts with heterogenous ribonucleoprotein K and with casein kinase 2. J. Biol. Chem. 1999; 274: 28991-8.
140. Zhi Y, Sandri-Goldin RM. Analysis of the phosphorylation sites of herpes simplex virus type 1 regulatory protein ICP27. J. Virol. 1999; 73: 3246-57.
141. Mitchell C, Blaho JA, Roizman B. Casein kinase JJ specifically nucleotidylylates in vitro the amino acid sequence of the protein encoded by the alpha 22 gene of herpes simplex virus 1. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 11864-8.
142. Morrison EE, Wang YF, Meredith DM. Phosphorylation of structural components promoters dissociation of the herpes simplex virus type 1 tegument. J. Virol. 1998; 72: 7108-14.
143. Das T, Schuster A, Schneider-Schaulies S, Banerjee AK. Involvement of cellular casein kinase II in the phosphorylation of measles virus P protein: identification of phosphorylation sites. Virology 1995; 211: 218-26.
144. Li M, Lyon MK, Garcea RL. In vitro phosphorylation of the Polyomavirus major capsid protein VP1 on serine 66 by casein kinase II. J. Biol. Chem. 1995; 270: 26006-11.
145. Byrappa S, Pan YB, Gupta KC. Sendai virus P protein is constitutively phosphorylated at serine 249: high phosphorylation potential of the P protein. Virology 1996; 216: 228-34.
146. Das T, Gupta AK, Sims PW, Gelfand CA, Jentoft JE, Banerjee AK. Role of cellular casein kinase II in the function of the phosphoprotein (P) subunit of RNA polymerase of vesicular stomatitis virus. J. Biol. Chem. 1995; 270: 24100-07.
147. Gotz C, Koenig MG, Issinger OG, Montenarh M. A casein-kinase-2-related protein kinase is tightly associated with the large T antigen of simian virus 40. Eur. J. Biochem. 1995; 233: 327-34.
148. Gupta AK, Das T, Banerjee AK. Casein kinase II is the P protein phosphorylating cellular kinase associated with the ribonucleoprtein complex of purified vesicular stomatitis virus. J. Gen. Virol. 1995; 76: 356-72.
149. Gao Y, Lenard J. Multimerization and transcriptional activation of the phosphoprotein (P) of vesicular stomatitis virus by casein kinase-II. EMBO J. 1995; 14: 1240-7.
150. Stevenson D, Xue M, Hay J, Ruyechan WT. Phosphorylation and nuclear localization of the varicella-zoster virus gene 63 protein. J. Virol. 1996; 70: 658-62.
151. Okuno T. Efficacy of interferon combined glycyrrhizin therapy in patients with interferon-resistant chronic hepatitis C. Nippon Rinsho. 1995; 53: 1022-5 (in Japanese).
152. Iino S, Tango T, Matsushima T, et al. Therapeutic effects of stronger-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol. Res. 2001; 19: 31-40.
153. Mahmood S, Niiyama G, Kawanaka M. et al. Long term follow-up of a group of chronic hepatitis C patients treated with anti-inflammatory drugs following initial interferon therapy. Hepatol. Res. 2002; 24: 213-9.
154. Fujioka T, Kondou T, Fukuhara A, Tounou S, Mine M, Mataki N, Hanada K, Ozaka M, Mitani K, Nakaya T, Iwai T, Miyakawa H. Efficany of a glycyrrhizin suppository for the treatment of chronic hepatitis C: a pilot study. Hepatol. Res., 2003; 26: 10-14.
155. Van Rossum TG, Vulto AG, Fop WC, Schalm SW. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am. J. Gastroenterol. 2001; 96: 2291-2.
156. Sasaki H, Takei M, Kobayashi M, Pollard RB, Suzuki F. Effect of glycyrrhizin, an active component of licorice roots, on HIV replication in cultures of peripheral blood mononuclear cells from HIV-seropositive patients. Pathbiol. 2002; 22: 229-36.
157. Zhang L, Wang B, K. Randomized clinical rial with two doses (100 and 40 ml) of stronger neominophagen C in chinease patients with chronic hepatitis B. Hepatol. Res. 2002; 24: 220-7.
158. Ito M, Sato A, Hirabayashi K, Tanabe F, Shigeta S, Baba M, Yamamoto N. Mechanism of inhibitory effect of glycyrrhizin on replication of HIV. Antiviral Res. 1988; 10: 289-98.
159. Ohtsuki K, Maekawa T, Harada S, Karino A, Morikawa Y, Ito M. Biochemical characterization of HIV-1 Rev as a potent activator of CK-II in vitro. FEBS lett. 1998; 428: 235-40.
160. Critchfield JW, Coligan JE, Folks TM, Butera ST. Casein kinase II is a selective target of HIV-1 transcriptional inhibitors. Proc. Natl. Acad. Sci. USA 1997; 94: 6110-5.
161. Sato H, Goto W, Yamamura J, Kurokawa M, Kageyama S, Takahara T. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res. 1996; 30: 171-7. (Pubitemid 26178135)
162. Shinada M, Azuma M, Kawai H, Sazaki K, et al. Enhancement of
163. Hayashi K, Hayashi R, Maruyama K, Yanigasawa N. Histopathologic and MRI findings in hypokalemic myopathy induced by glycyrrhizin. Acta Neurol. Scand. 1995; 92: 127-31.
164. Hayashi R. Myotonic and repetitive discharges in hypokalemic myopathy associated with glycyrrhizin-induced hypochloremia. J. Neurol. Sci. 1992; 107: 74-7.
165. Tanahashi T, Mune T, Morita H, Tanahashi H, Isomura Y, Suwa T, Daido H, Gomez-Sanchez CE, Yasuda K. Glycyrrhizic acid suppresses type 2 11β-hydroxysteroid dehydrogenase expression in vivo. J. Steroid Biochem. Mol. Biol. 2002; 80: 441-7. (Pubitemid 34442606)
166. Oh C, Kim Y, Eun J, Yokoyama T, Kato M, Nakashima I. Induction of T lymphocyte apoptosis by treatment with glycyrrhizin. Am. J. Chin. Med. 1999; 27: 217-26.
167. Guyton KZ, Kensler TW. Prevention of liver cancer. Curr. Oncol. Rep. 2002; 4: 464-70 (Review).
168. Kimura M, Inoue H, Hirabayashi K, Natsume H, Ogihara M. Glycyrrhizin and some analogues induce growth of primary cultured adult rat hepatocytes via epidermal growth factor receptors. Eur. J. Pharmacol. 2001; 431: 151-61.
169. Jung GD, Yang JY, Song ES, Par JW. Stimulation of melanogenesis by glycyrrhizin in B16 melanoma cells. Exp. Mol. Med. 2001; 33: 131-5.
170. Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology, 2002; 62: 94-100. (Pubitemid 34702027)
171. Kobayashi M, Fujita K, Katakura T, Utsunomiya T, Pollard RB, Suzuki F. Inhibitory effect of glycyrrhizin on experimental pulmonary metastasis in mice inoculated with B16 melanoma. Anticancer Res. 2002; 22: 4053-8.